Literature DB >> 20009891

Pure papillary serous tumors of the endometrium: a clinicopathological analysis of 61 cases from a single institution.

Virginia Benito1, Amina Lubrano, Octavio Arencibia, Eva Elisa Alvarez, Laureano León, Norberto Medina, Juan Miguel Falcón, Orlando Falcón.   

Abstract

OBJECTIVE: The aim of this study was to evaluate the clinicopathological data and prognosis factors corresponding to patients with papillary serous carcinoma of the endometrium treated at a single institution.
METHODS: Medical and anatomopathological records were reviewed in the Department of Gynecological Oncology of the Canarian University Hospital between 1989 and 2006. Only pure cases of papillary serous carcinoma of the endometrium were included. Survival rates were analyzed using the Kaplan-Meier technique.
RESULTS: The study included 61 patients. Stages I, II, III, and IV were identified in 32.8%, 19.7%, 31.1%, and 8.2% of patients, respectively. Event-free survival rates after 5 and 10 years were 59% and 40%, respectively, with a median time of 83 months (95% confidence interval, 63-110). Relapse occurred in 40.5% of the patients. Overall survival rates after 5 and 10 years were 37.7% and 29%, respectively, with a median time of 55 months (95% confidence interval, 40-70). A univariate analysis showed that prognosis factors were tumor markers, stage, myometrial infiltration, lymphovascular invasion, and ganglia involvement. A multivariate analysis showed that tumor markers, stage, and myometrial infiltration had an independent influence on overall survival.
CONCLUSIONS: Papillary serous carcinoma of the endometrium is a very aggressive type of endometrial carcinoma that behaves more similar to ovarian carcinoma than to endometrial carcinoma. Tumor markers at diagnosis, stage, and myometrial infiltration mainly determine prognosis at our institution.

Entities:  

Mesh:

Year:  2009        PMID: 20009891     DOI: 10.1111/IGC.0b013e3181b7a1d5

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  12 in total

1.  Prognostic factors in stages II/III/IV and stages III/IV endometrioid and serous adenocarcinoma of the endometrium.

Authors:  P Mhawech-Fauceglia; R F Herrmann; J Kesterson; I Izevbaye; S Lele; K Odunsi
Journal:  Eur J Surg Oncol       Date:  2010-12       Impact factor: 4.424

2.  Synuclein-γ (SNCG) protein expression is associated with poor outcome in endometrial adenocarcinoma.

Authors:  Paulette Mhawech-Fauceglia; Dan Wang; Susanna Syriac; Heidi Godoy; Nefertiti Dupont; Song Liu; Kunle Odunsi
Journal:  Gynecol Oncol       Date:  2011-10-19       Impact factor: 5.482

3.  Microarray analysis reveals distinct gene expression profiles among different tumor histology, stage and disease outcomes in endometrial adenocarcinoma.

Authors:  Paulette Mhawech-Fauceglia; Dan Wang; Joshua Kesterson; Kimberly Clark; Laketa Monhollen; Kunle Odunsi; Shashikant Lele; Song Liu
Journal:  PLoS One       Date:  2010-11-08       Impact factor: 3.240

4.  Gene expression profiles in stage I uterine serous carcinoma in comparison to grade 3 and grade 1 stage I endometrioid adenocarcinoma.

Authors:  Paulette Mhawech-Fauceglia; Dan Wang; Joshua Kesterson; Susanna Syriac; Kimberly Clark; Peter J Frederick; Shashikant Lele; Song Liu
Journal:  PLoS One       Date:  2011-03-23       Impact factor: 3.240

5.  Malignant endometrial polyps: Report of two cases and review of literature with emphasize on recent advances.

Authors:  Ali Dastranj Tabrizi; Amir Vahedi; Hiedar Ali Esmaily
Journal:  J Res Med Sci       Date:  2011-04       Impact factor: 1.852

6.  Claudin7 and moesin in endometrial Adenocarcinoma; a retrospective study of 265 patients.

Authors:  Paulette Mhawech-Fauceglia; Dan Wang; Shashikant Lele; Peter J Frederick; Tanja Pejovic; Song Liu
Journal:  BMC Res Notes       Date:  2012-01-24

7.  Pair-Box (PAX8) protein-positive expression is associated with poor disease outcome in women with endometrial cancer.

Authors:  P Mhawech-Fauceglia; D Wang; D Samrao; H Godoy; T Pejovic; S Liu; S Lele
Journal:  Br J Cancer       Date:  2012-05-29       Impact factor: 7.640

8.  Prognostic importance of DNA ploidy and DNA index in stage I and II endometrioid adenocarcinoma of the endometrium.

Authors:  M Pradhan; V M Abeler; H E Danielsen; B Sandstad; C G Tropé; G B Kristensen; B Å Risberg
Journal:  Ann Oncol       Date:  2011-09-30       Impact factor: 32.976

9.  Comparison of Risk Factors and survival of Type 1 and Type II Endometrial Cancers.

Authors:  Tahira Y Malik; Uzma Chishti; Aliya B Aziz; Irfan Sheikh
Journal:  Pak J Med Sci       Date:  2016 Jul-Aug       Impact factor: 1.088

10.  Clinicopathological and survival analysis of uterine papillary serous carcinoma: a single institutional review of 106 cases.

Authors:  Yao Wang; Mei Yu; Jia-Xin Yang; Dong-Yan Cao; Keng Shen; Jing-He Lang
Journal:  Cancer Manag Res       Date:  2018-10-25       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.